Anixa Biosciences Secures WHO Approval for CAR-T Therapy Name
Anixa Biosciences Inc. has received WHO approval for the name "liraltagene autoleucel" for its CAR-T therapy targeting recurrent ovarian cancer. This approval is a key step towards commercialization, ensuring clear identification and safe prescription. The therapy is currently in Phase 1 clinical trials with Moffitt Cancer Center.
Anixa Biosciences Inc. announced that the World Health Organization (WHO) has approved the International Nonproprietary Name (INN) “liraltagene autoleucel” for its novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer. The assignment of this unique, globally recognized name marks a key milestone toward the potential future commercialization of the therapy. The INN approval ensures clear identification and safe prescription of the treatment as Anixa continues its ongoing Phase 1 clinical trial in partnership with Moffitt Cancer Center. No grant or funding announcement involving multiple organizations was included. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anixa Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA25412) on November 17, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
